Literature DB >> 15865268

Impact of severity of illness bias and control group misclassification bias in case-control studies of antimicrobial-resistant organisms.

Anthony D Harris1, Yehuda Carmeli, Matthew H Samore, Keith S Kaye, Eli Perencevich.   

Abstract

BACKGROUND: Case-control studies often analyze risk factors for antibiotic resistance. Recently published articles have illustrated that randomly selected control-patients may be preferable to those with the susceptible phenotype of the organism. A possible methodologic problem with randomly selected control-patients is potential bias due to control group misclassification. This occurs if some control-patients did not have clinical cultures performed and thus might have been unidentified case-patients. If this bias exists, these studies might be expected to report lower odds ratios (ORs) because control-patients would be more like case-patients.
OBJECTIVE: To analyze potential biases that might arise due to control group misclassification and potentially larger selection biases that may be introduced if control-patients are required to have at least one clinical culture. PATIENTS: One hundred twenty case-patients, 770 control-patients in group 1, and 510 control-patients in group 2.
METHODS: Two case-control studies. Case-patients had clinical cultures positive for imipenem-resistant Pseudomonas aeruginosa. The first group of control-patients were random. The second group of control-patients were identical to those in group 1 except being required to have at least one clinical culture.
RESULTS: Univariate analyses showed higher ORs for case-patients versus control-patients in group 1 (imipenem [OR, 12.5], piperacillin-tazobactam [OR, 3.7], and vancomycin [OR, 4.7]) as compared with case-patients versus control-patients in group 2 (imipenem [OR, 8.0], piperacillin-tazobactam [OR, 2.5], and vancomycin [OR, 3.0]).
CONCLUSION: Requiring control-patients to have at least one clinical culture introduces a selection bias likely because it eliminates patients with less severe illness.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15865268     DOI: 10.1086/502549

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  12 in total

1.  Case-case-control study of patients with carbapenem-resistant and third-generation-cephalosporin-resistant Klebsiella pneumoniae bloodstream infections.

Authors:  Jason C Gallagher; Safia Kuriakose; Kevin Haynes; Peter Axelrod
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

Review 2.  Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.

Authors:  Vered Schechner; Elizabeth Temkin; Stephan Harbarth; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

3.  Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections.

Authors:  Marlieke E A de Kraker; Martin Wolkewitz; Peter G Davey; Walter Koller; Jutta Berger; Jan Nagler; Claudine Icket; Smilja Kalenic; Jasminka Horvatic; Harald Seifert; Achim J Kaasch; Olga Paniara; Athina Argyropoulou; Maria Bompola; Edmond Smyth; Mairead Skally; Annibale Raglio; Uga Dumpis; Agita Melbarde Kelmere; Michael Borg; Deborah Xuereb; Mihaela C Ghita; Michelle Noble; Jana Kolman; Stanko Grabljevec; David Turner; Louise Lansbury; Hajo Grundmann
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

4.  Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.

Authors:  Thomas P Lodise; Christopher D Miller; Jeffrey Graves; Jon P Furuno; Jessina C McGregor; Ben Lomaestro; Eileen Graffunder; Louise-Anne McNutt
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

5.  Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship.

Authors:  Dror Marchaim; Teena Chopra; Ashish Bhargava; Christopher Bogan; Sorabh Dhar; Kayoko Hayakawa; Jason M Pogue; Suchitha Bheemreddy; Christopher Blunden; Maryann Shango; Jessie Swan; Paul R Lephart; Federico Perez; Robert A Bonomo; Keith S Kaye
Journal:  Infect Control Hosp Epidemiol       Date:  2012-06-11       Impact factor: 3.254

Review 6.  Multidrug-Resistant Bacteria in the Community: Trends and Lessons Learned.

Authors:  David van Duin; David L Paterson
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

7.  Changes in transfusion practice over time in the PICU.

Authors:  Michael D Dallman; Xinggang Liu; Anthony D Harris; John R Hess; Bennett B Edelman; David J Murphy; Giora Netzer
Journal:  Pediatr Crit Care Med       Date:  2013-11       Impact factor: 3.624

8.  Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes.

Authors:  Dror Marchaim; Shiri Navon-Venezia; Mitchell J Schwaber; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

Review 9.  Antimicrobial agent exposure and the emergence and spread of resistant microorganisms: issues associated with study design.

Authors:  C Angebault; A Andremont
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-12-27       Impact factor: 3.267

10.  Biofilms and persistent wound infections in United States military trauma patients: a case-control analysis.

Authors:  Kevin S Akers; Katrin Mende; Kristelle A Cheatle; Wendy C Zera; Xin Yu; Miriam L Beckius; Deepak Aggarwal; Ping Li; Carlos J Sanchez; Joseph C Wenke; Amy C Weintrob; David R Tribble; Clinton K Murray
Journal:  BMC Infect Dis       Date:  2014-04-08       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.